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Long-term exposure to estrogen and its metabolites may play an
important role in renal cell carcinogenesis. Catechol-O-methyl-
transferase (COMT) participates in the estrogen metabolism
pathway by neutralizing toxic substances. Although reduced
COMT activity has been suggested to be a risk factor for estro-
gen-associated cancers, no studies have investigated the biological
significance of COMT in the pathogenesis of human renal cell
cancers (RCCs). We initially found that COMT levels are signif-
icantly decreased in human RCC tissues and cells suggesting it
plays a suppressive role in tumor development. However, tran-
sient overexpression of COMT has no functional effect on RCC
cell lines. In contrast, when cells overexpressing COMT are trea-
ted with its substrate 4-hydroxyestradiol (4-OHE2), growth is in-
hibited by apoptotic cell death. We also found that COMT
overexpression combined with 4-OHE2 induces upregulation of
growth arrest- and DNA damage-inducible protein a (GADD45a).
We further show that downregulation of GADD45a by a small
interfering RNA-mediated approach inhibits cell death, indicat-
ing the essential role of GADD45a in the underlying mechanism
of COMTaction in response to 4-OHE2. Finally, 4-methoxyestradiol
fully reproduces the antiproliferative function of COMT with
4-OHE2 by promoting GADD45a induction. Together, these find-
ings show that COMT in the presence of 4-OHE2 prevents RCC
cell proliferation by enhancing apoptosis and that GADD45a
plays a critical role in the COMT-mediated inhibition of RCC.
Introduction
In the USA, kidney cancer is among the 10 most common cancers in
both men and women. It is estimated that 60 920 new cases and
13 120 deaths from the disease will occur in 2011 (1). Renal cell
cancer (RCC) is the most frequent type of kidney cancer and 80%
of RCC are clear cell adenocarcinomas, the remainder being papillary
(15%), chromophobe (5%) and collecting duct carcinomas (,1%)
(2). Genetic susceptibility, cigarette smoking, obesity, hypertension,
chronic renal failure and occupational exposure to trichloroethylene
have been considered as strong risk factors for RCC (1,2). There are
almost twice as many RCC cases in men as in women, and men
generally present with more severe malignancy, such as larger size,
higher grade and higher stage of tumors than women. In addition, the
mean age at diagnosis for men is slightly earlier and both overall and
5 years survival rate is also shorter than that of women (3,4). Although
the reason for difference in rates of RCC between men and women
remains unknown, there is substantial evidence suggesting that
estrogen may be an additional etiological factor for RCC, espe-
cially in men. According to a report by Lipworth et al. (2), the
average age at RCC diagnosis is in the early 60s and men at this
age have much higher levels of estrogen compared with post-
menopausal women of similar age (5,6). Renal carcinoma has been
found in male patients who had received long-term estrogen ther-
apy for treating prostatic carcinoma (7,8). However, no association
of RCC risk with estrogen replacement therapy in women was
observed (9). In the golden Syrian hamster, kidney tumors are
normally produced only in males treated with synthetic estrogen
and the induction of tumor can be blocked by the administration of
estrogen antagonists (10,11).
In extrahepatic tissues including kidney, endogenous estrogens
undergo oxidative metabolism catalyzed by cytochrome P450
1A1 and 1B1 to yield catechol estrogens, 2-hydroxyestradiol and
4-hydroxyestradiol (4-OHE2), respectively. Of the two catechol
estrogens, 4-OHE2 is believed to be a critical intermediate in es-
trogen-induced cancers. It is further oxidized by metabolic redox
cycling, and the resultant estradiol-3,4-quinones and reactive oxy-
gen species have genotoxic and carcinogenic effects (12). 4-OHE2
is also capable of inducing cytotoxicity in human mammary epi-
thelial cells and activation of nuclear factor-kappaB and extracel-
lular signal-regulated kinase/mitogen-activated protein kinase
pathways (13).
Catechol-O-methyltransferase (COMT) is a phase II enzyme in
the process of estrogen metabolism. It catalyzes O-methylation at
either the 2-, 3-, 4-position of the catechol ring of a substrate and
thus, methoxyestradiols (MEs) are produced from corresponding
hydroxyestradiols (14). It has been suggested that COMT may pre-
vent the development of estrogen-associated cancers by this meta-
bolic O-methylation of endogenous catechol estrogens. It reduces
the level of 4-OHE2, thereby lowering the potential for genomic
damage through DNA adduct formation or through oxygen radicals
arising from quinone–semiquinone redox cycling of catechol estro-
gen (15,16). 2-ME, which is produced from 2-OHE2 has antiproli-
ferative, antiangiogenic and proapoptotic activity in multiple types
of cancer (17). There is evidence for the protective role of COMT in
estrogen-induced carcinogenesis. Administration of a COMT inhib-
itor, quercetin, increased the number of large renal tumors and the
incidence of abdominal metastases in estradiol-treated hamsters
(18,19). COMT also protects catechol estrogen-induced malignant
transformation of human endometrial glandular cells by regulating
oxidative stress (20). Salama et al. (21) showed that 2-ME produced
by COMT overexpression ameliorates estradiol-induced prolifera-
tion of human uterine leiomyoma cells by disturbing microtubule
dynamics, inhibiting steroid receptor signaling and reducing HIF-1a
and CYP19 expression.
The association of COMT polymorphisms with the risk of various
cancers of the breast, endometrium, prostate, bladder, liver, stomach
and esophagus has been investigated. Recently, we found that a COMT
polymorphic variant, which may alter messenger RNA (mRNA) sta-
bility and/or translation efficiency, is significantly associated with risk
for RCC in men (22). Therefore in this study, we examined the ex-
pression level and functional significance of COMT in human RCC.
Our results show that both the mRNA and protein levels of COMT are
significantly decreased in RCC. Although overexpression alone has
no obvious effect, COMT expression in the presence of 4-OHE2 in-
hibits the proliferation of RCC cells, which results from increased
apoptotic cell death. In addition, the critical role of 4-ME formation
and subsequent growth arrest- and DNA damage-inducible protein a
(GADD45a) induction as the underlying mechanism of COMT action
were demonstrated.
Abbreviations: cDNA, complementary DNA; COMT, catechol-O-methyl-
transferase; FITC, fluorescein isothiocyanate; GADD45a, growth arrest- and
DNA damage-inducible protein a; 4-OHE2, 4-hydroxyestradiol; ME, methox-
yestradiol; mRNA, messenger RNA; PCR, polymerase chain reaction; Q-PCR,
quantitative PCR; RCC, renal cell cancer; siRNA, small interfering RNA.
 The Author 2011. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com 420
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Materials and methods
Cell lines and reagents
The immortalized human renal proximal tubule epithelial cell line, HK-2, renal
cancer cell lines, Caki-1, ACHN and 769-P, and a prostate cancer cell line,
LNCaP were obtained from the American Type Culture Collection (Manassas,
VA). Keratinocyte serum-free medium, bovine pituitary extract and
recombinant epidermal growth factor were purchased from Invitrogen
(Carlsbad, CA). McCoy’s 5A, Eagle’s minimum essential medium with
Eagle’s balanced salts solution (EMEM), RPMI 1640, Opti-minimum essential
medium and penicillin/streptomycin mixtures were obtained from the UCSF
Cell Culture Facility. Phenol red-free McCoy’s 5A and Eagle’s minimum
essential media were purchased from PromoCell (Heidelberg, Germany) and
Invitrogen, respectively. Fetal bovine serum was a product of Atlanta Biolog-
icals (Lawrenceville, GA). 4-OHE2 and Ro 41-0960 were purchased from
Sigma Chemical Co. (St Louis, MO). 4-ME was obtained from
Steraloids (Newport, RI).
Cell culture
The HK-2 cell line was maintained in keratinocyte serum-free medium supple-
mented with 0.05 mg/ml bovine pituitary extract and 5 ng/ml recombinant
epidermal growth factor. The Caki-1 and ACHN cell lines were grown in
McCoy’s 5A and Eagle’s minimum essential medium, respectively. The 769-P
and LNCaP cell lines were cultured in RPMI 1640 medium. All culture medium
contained 10% fetal bovine serum and 100 lg/ml penicillin/streptomycin
mixture. All cell lines were maintained at 37C in a humidified atmosphere
composed of 5% CO2/95% air.
Establishment of RCC cell lines stably expressing COMT
Caki-1 and ACHN cells were transfected with pCMV6-ENTRY vector ex-
pressing the C-terminally Myc and Flag-tagged human membrane bound
(MB)-COMT complementary DNA (cDNA) as well as empty pCMV6-EN-
TRY vector as a control (OriGene Techologies, Rockville, MD) using Fugene
HD Transfection Reagent (Roche Diagnostics, Indianapolis, IN) according to
the manufacturer’s protocol. Stable clones were selected with 500 lg/ml of
G418 (Invitrogen). Colonies resistant to G418 appeared within 2 weeks, and
single colonies were picked and then expanded for another 3 weeks to make the
original stock cells.
Quantitative reverse transcription–polymerase chain reaction
Total RNA from cultured cell lines was isolated using the RNeasy Mini Kit
(Qiagen, Valencia, CA) and was converted into cDNA by using the iScriptTM
cDNA Synthesis Kit (Bio-Rad, Hercules, CA) according to the manufacturer’s
instruction. To assess gene expression, cDNAs were amplified with the Taq-
Man Gene Expression Assays and TaqMan Fast Universal polymerase
chain reaction (PCR) Master Mix using the 7500 Fast Real-Time PCR
System (Applied Biosystems, Foster City, CA). The target genes and their
Assay ID were as follows: COMT (Hs00241349_m1) and GADD45a
(Hs00169255_m1). Beta-actin was utilized to normalize COMT expression
in normal and RCC clear cell tissues and glyceraldehyde-3-phosphate dehy-
drogenase was used as an internal control unless stated otherwise. The relative
change in gene expression was calculated by the comparative Ct (threshold
cycle) method using the 7500 Fast System Sequence Detection Software (Ap-
plied Biosystems). For COMT mRNA expression in normal and RCC clear cell
tissues, TissueScanTM Kidney Cancer cDNA Arrays (OriGene Techologies)
were subjected to quantitative polymerase chain reaction (Q-PCR) analysis.
For investigation of gene expression profiling of selected apoptosis-related
genes, the Human Apoptosis RT2 Profiler PCR Array (SABiosciences, Fred-
erick, MD) was used as per manufacturer’s instructions. In brief, total RNA
extracted from Caki-1/pCMV6 and Caki-1/COMT cells after 4-OHE2 (50 lM)
treatment for 48 h was converted into cDNA by using the RT2 First Strand Kit.
Q-PCR analysis was performed with RT2 Real-TimeTM SYBR Green/Rox PCR
master mix. Gene expression levels were determined by using the data analyzer
template provided by SABiosciences.
Western blot analysis
Whole-cell extracts were prepared using radioimmunoprecipitation assay
buffer (Thermo Scientific, Rockford, IL) containing protease inhibitor cocktail
(Roche Diagnostics). Total protein (40 lg) was loaded onto 12% Bis–Tris Gels
with 3-(N-morpholino)propanesulfonic acid buffer and separated by a NuPAGE
elecrophoresis system (Invitrogen). Protein was transferred to InvitrolonTM
polyvinylidene difluoride and immunoblotting was carried out according to
standard protocols. The antibodies used for immunoblotting were rabbit poly-
clonal antibody raised against COMT (Sigma–Aldrich, St Louis, MO) and
GADD45a (Cell Signaling Technology, Danvers, MA), and mouse monoclonal
antibody against GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA) was
used to confirm equal loading.
Immunohistochemistry
Immunostaining was performed on a formalin-fixed paraffin-embedded kid-
ney cancer tissue array (US Biomax, Rockville, MD) using the ImmunoCruz
Staining System (Santa Cruz Biotechnology). Briefly, the sections were de-
paraffinized in xylene and rehydrated in graded alcohols, followed by rinsing
in dH2O. After antigen retrieval by microwaving, endogenous peroxidase
activity was quenched with H2O2 and rinsed with washing buffer. Normal
goat serum was applied to minimize non-specific binding. The sections were
incubated overnight at 4C with rabbit polyclonal anti-COMT antibody
(Sigma Life Sciences, St Louis, MO) diluted 1:250 in serum block followed
by biotinylated anti-rabbit antibody. After incubation with horseradish per-
oxidase–streptavidin complex, Ultravision Plus DAB Plus Substrate System
(Labvision, Fremont, CA) was added as chromogen followed by counter-
staining with hematoxylin. Staining intensity of each tissue section was vi-
sually evaluated under an Olympus BX60 microscope equipped with Spot
Advanced software (Diagnostic Instruments, Sterling Heights, MI) and was
ranked on an overall scale from 0 to 3; with 0 indicating the absence of
staining; 1, weak staining; 2, moderate staining and 3, strong staining. As-
sessment of the staining pattern was adapted and modified from the study of
Fisher et al. (23). In brief, the presence or absence of staining, depth of color
and the number of cells showing a positive reaction were recorded. Dark
cytoplasmic staining that is easily visible with a low power objective and
involves .50% of cells was considered as strong, focal dark staining areas
(,50% of cells) or moderate cytoplasmic staining of .50% of cells was
classified as moderate and focal moderate staining in ,50% of cells or pale
cytoplasmic staining in any proportion of cells not easily seen under a low
power was categorized as weak.
Cell proliferation assay
Cells were plated in triplicate in 96-well microplates at a density of 5 103 cells
per well in phenol red-free media supplemented with 10% charcoal-stripped
fetal bovine serum (Invitrogen). The cells were then treated with 50 lM of
either 4-OHE2 or 4-ME. At the desired time point, the number of viable cells
was determined by adding 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium-based CellTiter 96 AQueous One
Solution Reagent (Promega, Madison, WI) to each well and measuring the
absorbance at 490 nm on SPECTRA MAX 190 plate reader (Molecular Devices,
Sunnyvale, CA). Results were expressed as the percentage of optical density,
assuming that the absorbance of control cells was 100%. The working concen-
tration of 4-OHE2 and 4-ME was selected based on concentration–response
studies (Supplementary Figure 1 is available at Carcinogenesis Online). In brief,
cells were treated with 1, 10, 20, 50 and 100 lM of 4-OHE2 or 2, 10, 20, 30 and
50 lM of 4-ME and cell proliferation was determined by 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay. As
a result, 50 lM was chosen for both since it showed the most significant growth
inhibitory effect on cells.
Apoptosis assay
Apoptosis was analyzed with an Annexin V-fluorescein isothiocyanate (FITC)/
7-amino-actinomycin D staining system obtained from BD Biosciences (San
Diego, CA). Briefly, cells were harvested and resuspended in binding buffer at
a concentration of 1  106 cells/ml. For each assay, 1  105 cells were in-
cubated with 5 ll of Annexin V-FITC and 20 ll of 7-amino-actinomycin D in
the dark for 15 min at room temperature. After adding 400 ll of 1 binding
buffer, samples were analyzed within an hour by a Cell Lab QuantaTM SC MPL
(Beckman Coulter, Fullerton, CA).
Small interfering RNA transfection
When a cell density of 30–50% confluence was reached, small interfering RNA
(siRNA) duplexes specific for human GADD45a or universal scrambled
negative control (OriGene Techologies) was transfected using Lipofectamine
2000 Transfection Reagent (Invitrogen) as described by the manufacturer’s
instructions. Target specificity and knockdown efficiency were evaluated by
both real-time PCR and western blotting with three different sets of siRNA
duplexes at different concentrations. The siRNA duplex at a concentration of
20 nM showing the most efficient GADD45a knock down was selected and
used for further experiments. Cells treated with Lipofectamine 2000 Trans-
fection Reagent alone were included as a mock control for each experiment.
Statistical analysis
Values are presented as the mean ± standard error of mean based on results
obtained from at least three independent experiments. Statistical significance
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was evaluated by conducting a two-tailed unpaired Student’s t-test using
GraphPad PRISM Software. P , 0.05, P , 0.01, P , 0.001, n.s,
non-significant.
Results
COMT expression is downregulated in RCC tissues and cell lines
Given that a polymorphic variant of COMT, with a potential to alter
its expression, is a risk factor for RCC (22), we initially examined
whether COMT levels are changed in RCC tissues. Q-PCR studies
showed significantly decreased expression of COMT mRNA in clear
cell RCC compared with normal renal cells (Figure 1A). As previ-
ously reported (24), immunohistochemical staining of COMT protein
was predominantly observed in proximal convoluted tubules in the
juxtamedullary cortex (Figure 1B, left). Although we are unable to
distinguish COMT isoforms, most of the immunoreactive COMT was
located in the cytoplasm, with only occasional cell nuclei showing
positive staining in normal renal cells (Figure 1B, left). In contrast,
weak or no expression of COMT protein was observed in clear cell
RCC tissues with average staining scores of 0.37 ± 0.16 (versus 2.63 ±
0.13 in normal tissues) (Figure 1B, right). The relative COMT expres-
sion levels in RCC cell lines were also compared with the immortal-
ized kidney tubule epithelial cell line HK-2. Consistent with the
observation in tissues, both COMT mRNA and protein levels were
lower in RCC cell lines than in HK-2 cells (Figure 1C and D, re-
spectively). The COMT protein occurs as two distinct forms, in the
cytoplasm as a soluble protein and in association with membranes,
mainly in the rough endoplasmic reticulum as a membrane-bound
form (25). The human soluble (S)-COMT protein contains 221 amino
acids and MB-COMT protein has 50 additional amino acids residues.
Thus, their molecular weights are 25 and 30 kDa, respectively (25).
Although both forms of COMT are expressed in equal amounts in
human kidney (25), MB-COMT is predominantly expressed in both
HK-2 and RCC cell lines (Figure 1D). These results showing lower
COMT expression in cancer tissue and cells suggest that COMT may
play a suppressive role in RCC tumorigenesis.
COMT overexpression enhances 4-OHE2-mediated growth inhibition
of RCC cells
Reduced expression of COMT in RCC tissues and cell lines led us to
examine whether increased levels of COMT affects the growth of
RCC. Since the majority of COMT is present as the MB form in
RCC cell lines, we transiently transfected a plasmid containing human
MB-COMT into Caki-1 cells, which has low level of endogenous
COMT, and assessed the growth rate of the cells. However, there were
no changes in proliferation, apoptosis and the cell cycle by transient
upregulation of COMT in Caki-1 cells (data not shown).
Since COMT catalyzes the O-methylation of 2- or 4-OHE2 and
produces 2- or 4-ME, respectively (12), it may affect the growth of
RCC in the presence of its metabolic substrates. Indeed, production of
2-ME by COMT expression inhibits the 17b-estradiol-induced pro-
liferation of human uterine leiomyoma cells (21). However, a few
studies have investigated the effect of 4-OHE2 metabolism and
4-ME on cancer cell growth (26,27). Therefore, we explored the
growth-inhibitory effect of 4-OHE2 on COMT overexpressing RCC
cells. To investigate this possibility, we first established Caki-1 and
ACHN cell lines stably overexpressing MB-COMT. As shown in
Figure 2A, a significant amount of exogenous protein was detected
by western blotting in COMT-transfected RCC cell lines (Caki-1/
COMT and ACHN/COMT) but not in control vector-transfected
cells (Caki-1/pCMV6 and ACHN/pCMV6). Next, we treated the
stable COMT-expressing cell lines with 4-OHE2 and examined cell
proliferation. Overexpression of COMT significantly enhanced the
level of growth inhibition that occurs in response to 4-OHE2 in
Fig. 1. Reduced COMT expression in RCC tissues and cells. (A) COMT mRNA expression in normal kidney and RCC clear cell tissues. Q-PCR was performed with
TissueScanTM Kidney Cancer cDNA Arrays. COMT signal was normalized to b-actin expression. (B) Immunohistochemical staining of COMT protein expression.
Kidney cancer tissue array was immunostained with COMT antibody and counterstained with hematoxylin. Left, representative images showing immunoreactive
COMT in normal and RCC clear cell tissues (magnification: 200). Right, summary of COMT immunostaining score. Staining intensity was assessed as described
under ‘Materials and methods’. (C) Relative expression of COMT mRNA in RCC cell lines. Total RNA was extracted from the indicated cell lines and subjected to
quantitative reverse transcription–PCR analysis. COMT signals were normalized to GAPDH. Data are presented as fold increase relative to COMT expression in
HK-2 cells. (D) A representative immunoblot displaying COMT expression in RCC cell lines and LNCaP cells. LNCaP cells were used as a positive control to detect
the two isoforms of COMT. MB-COMT: membrane-bound form of COMT; S-COMT: soluble form of COMT. Values are presented as the mean ± standard error of
mean of three experiments. Asterisks denote statistically significant differences between the compared values: P , 0.05, P , 0.01, P , 0.001.
I.Chang et al.
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a time-dependent manner (Figure 2B). Pretreatment of cells with
COMT-specific inhibitor, Ro 41-0960 reversed the 4-OHE2-mediated
decrease of cell number suggesting this observation could be a COMT-
specific effect (Figure 2C). As indicated in Figure 2D, 4-ME clearly
caused growth inhibition of parental Caki-1 and ACHN cells. Thus,
our data suggest that COMT inhibits the growth of RCC cells in the
presence of 4-OHE2 by producing 4-ME.
4-OHE2 induces apoptotic cell death in COMT overexpressing RCC
cells
Growth inhibition may result from the increase in cell cycle arrest
and/or apoptotic cell death.
To further understand the growth-inhibitory effect of 4-OHE2, we
examined cell cycle distribution and mode of cell death by flow cyto-
metric analysis. It was observed that 4-OHE2 treatment leads to no
change in cell cycle progression (data not shown). In contrast, the
apoptotic cell fractions, which were stained with Annexin V-FITC only
(early apoptotic) or both Annexin V-FITC and 7-amino-actinomycin D
(late apoptotic), were significantly increased in 4-OHE2 treated cells
(Figure 3A and B). Ro 41-0960 reduced the 4-OHE2-mediated apopto-
tic cell death (Figure 3B). These results suggest that 4-OHE2-mediated
growth inhibition results from increased apoptosis in COMT-expressing
RCC cells.
4-OHE2 upregulates GADD45a in COMT overexpressing RCC cells
To gain insight into the underlying mechanisms of the COMT-mediated
growth inhibition of RCC cells, we examined changes in gene
expression in Caki-1/COMT cells exposed to 4-OHE2 using the
Human Apoptosis RT2 Profiler PCR Array containing Q-PCR pri-
mers of 84 known apoptosis-related genes. From the genes analyzed,
the expression of eight genes was significantly increased and among
them, GADD45a was greatest at 8.6-fold (Table I).
To verify the array data, we performed Q-PCR assay with a different
probe than the one used in the PCR array. Consistently, a robust in-
crease of GADD45a mRNA expression was detected in both Caki-1/
COMT (7.8-fold) and ACHN/COMT cells (5.5-fold) (Figure 4A).
Next, we explored whether the 4-OHE2-induced elevation in
GADD45a mRNA is associated with an increase in protein level.
As shown by western blotting, GADD45a protein expression was
significantly increased by exposure to 4-OHE2 in both Caki-1/COMT
and ACHN/COMT cells (Figure 4B). Furthermore, 4-ME promoted
GADD45a protein expression in parental Caki-1 and ACHN cells
(Figure 4C). Since GADD45a was the most dramatically regulated
gene among those examined, we hypothesized that GADD45a may
play a pivotal role in growth inhibition by 4-OHE2 in COMT over-
expressing RCC cells.
Inhibition of GADD45a prevents apoptotic cell death by 4-OHE2 in
COMT overexpressing RCC cells
To determine whether GADD45a is a key effector in the 4-OHE2
metabolism-mediated downstream signaling pathways, we measured
apoptotic cell death by exploiting GADD45a siRNA to selectively
knock down GADD45a in RCC cells. We first confirmed the ability of
siGADD45a duplexes to suppress endogenous GADD45a level. Ad-
ministration of GADD45a siRNA to COMT overexpressing RCC
cells decreased both basal mRNA (data not shown) and protein
(Figure 5A) expression. In the presence of control siRNA, 16–21%
of cells underwent apoptosis in response to 4-OHE2. COMT over-
expressing RCC cells treated with GADD45a siRNA, in contrast,
were refractory to the proapoptotic activity of 4-OHE2 (Figure 5A).
Furthermore, we examined the possible role of GADD45a in the
antiproliferative effect of 4-ME. GADD45a siRNA efficiently in-
hibited both basal GADD45a mRNA (data not shown) and protein
(Figure 5B) expression in parental Caki-1 and ACHN cells. Silencing
Fig. 2. Enhanced growth suppressive effect of COMT on RCC cells in the presence of 4-OHE2. (A) Ectopic expression of COMT in RCC cell lines. COMT
expression in stably transfected Caki-1 and ACHN cells with either COMT cDNA (Caki-1/COMT and ACHN/COMT) or empty vector (Caki-1/pCMV6 and
ACHN/pCMV6) were determined using western blot analysis. GAPDH was used as a control for protein loading. (B) Proliferation of Caki-1/COMT and ACHN/
COMT cells in response to 4-OHE2. Cells were treated with 4-OHE2 (50 lM) for the indicated times. (C) Effect of COMT inhibitor (Ro 41-0960) on the
proliferation of Caki-1/COMT and ACHN/COMT cells in response to 4-OHE2. Cells were exposed to 4-OHE2 (50 lM) in the absence or presence of Ro 41-0960
(20 lM) for 72 h. (D) Influence of 4-ME on the proliferation of parental Caki-1 and ACHN cells. Cells were treated with 4-ME (50 lM) for 72 h. The number of
viable cells were determined by reading the optical density produced with CellTiter 96 AQueous Assay. Values are expressed as mean ± standard error of mean of
three experiments. Asterisks denote statistically significant differences between the compared values: P , 0.05, P , 0.01.
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of the GADD45a gene by siRNA also prevented 4-ME-induced apo-
ptosis (Figure 5B). These results demonstrate that GADD45a is an
essential mediator of 4-OHE2-induced apoptosis in COMT overex-
pressing RCC cells.
Discussion
It has been suggested that reduced enzymatic activity and altered
expression of COMT are associated with the development and pro-
gression of various types of cancers. A polymorphic variant of COMT
that may affect gene expression as a result of a change in RNA
structure and thus, translation efficiency, could potentially lead to
human RCC (22). Therefore, in the present study, we determined
the expression level and functional significance of COMT in human
RCC.
In the human kidney, most of the COMT expression is found in the
cytoplasm of epithelial cells of convoluted tubules, in particular, of
the juxtamedullary cortex region, which corresponds to findings in rat
and hamster (24,28). A marked decrease of COMT expression in
human RCC tissues and cells is also consistent with other studies
observing no COMT immunoreactivity in hamster RCC (29,30). Al-
though the mechanisms causing the decrease in COMT gene expres-
sion are not fully understood, there are three possibilities: First,
estrogen regulates COMT expression and activity (30,31) and chronic
exposure to estrogen at high doses leads to estrogen-associated can-
cer. Therefore, it is conceivable that high levels of estrogen in cancer
patients may lead to COMT downregulation; second, there are many
polymorphisms that have been identified in the COMT gene. COMT
polymorphic variants in the coding region have been shown to result
in either reduced enzyme activity or structural changes in mRNA, and
as a result, cause altered protein expression (32,33). COMT polymor-
phism have been shown to correlate with RCC (22) and thus, variants
may lead to lower expression in cancer; and third, aberrant methyla-
tion of the promoter region of genes is one of the major mechanisms
for the loss of tumor suppressor gene function in human cancer (34).
According to Sasaki et al. (35), COMT expression can be inactivated
by CpG hypermethylation. Thus, analysis of the methylation status of
the COMT promoter in RCC may give insight into the regulatory
mechanism of COMT expression. However, despite these possibili-
ties, the mechanisms behind the decreased levels of COMT in renal
cancers are not clear and remain to be further defined.
In this study, we found that MB-COMT is predominantly expressed
in RCC cell lines. This is also observed in a human cervical cancer
(HeLa), malignant melanoma (SK-MEL-5), colon adenocarcinoma
(Colo 320DM), neuroblastoma (IMR-32) and bone marrow (KG-1)
cell lines (25). Whether this selective expression pattern is the case for
RCC tissues is unknown since the antibody we used in the immuno-
histochemistry study detects both MB- and S-COMT, and high quality
of antibodies which can specifically detect one of the isoforms are not
commercially available.
It has been suggested that COMT may contribute to prevent the
development of cancers in two ways. First, it reduces the level of
4-OHE2, thereby lowering the potential for genomic damage through
DNA adduct formation or through oxygen radicals arising from qui-
none–semiquinone redox cycling of catechol estrogen (15,16). Sec-
ond, it converts 2-OHE2 to 2-ME, which has antiproliferative,
antiangiogenic and proapoptotic effects on multiple types of cancer
(17). Unlike 2-ME, the biological function of 4-ME is largely un-
known. Since it has little effect in experimental conditions where
2-ME is highly effective, 4-ME is believed to be primarily an end
product of the COMT-mediated clearing mechanism of 4-OHE2.
However, in studies by Zhu et al. (36) and Dawling et al. (37),
4-ME serves as a substrate for 4-OHE2 formation by demethylation
catalyzed by CYP1B1. Moreover, Cheng et al. (38) showed that 4-ME
can inhibit growth of human lung epithelial cells by inducing oxida-
tive DNA damage via reactive oxygen species production.
Aside from the functions previously reported, the roles of 4-ME as
an effective inhibitor of proliferation and an initiator of apoptosis in
human RCC are newly discovered. Treatment of renal cancer cells
with 4-ME fully mimicked the growth inhibition by GADD45a
Table I. Summary of apoptosis-related genes significantly increased by
4-OHE2 stimulation in Caki-1/COMT cells
Gene namea Fold changeb P value
GADD45A 8.6 ,0.001
LTA 4.2 ,0.001
TRAF2 3.6 ,0.05
TNFRSF10A 2.5 ,0.01
BCL2A1 2.1 ,0.01
AKT1 2.0 ,0.001
BCL2L1 2.0 ,0.001
CIDEB 2.0 ,0.05
aGenes identified as increased 2-fold are listed.
bFold change represents the ratio of signal in 4-OHE2-treated Caki-1/COMT
relative to Caki-1/pCMV6 cells for each primer set.
Fig. 3. 4-OHE2-induced apoptotic cell death in COMT overexpressing RCC cells. Caki-1/COMT cells exposed to 4-OHE2 (50 lM) with or without Ro 41-0960
(20 lM) for 72 h were subjected to flow cytometric analysis using double staining with Annexin V-FITC and 7-amino-actinomycin D (7-AAD). (A) A
representative biparametric histogram showing cell population in early (bottom right quadrant) and late (top right quadrant) apoptotic and viable (bottom left
quadrant) states. (B) Percent of total apoptotic cells. Values are expressed as mean ± standard error of mean of three experiments. Asterisks denote statistically
significant differences between the compared values: P , 0.05, P , 0.01.
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upregulation which were mediated by 4-OHE2 in COMT overexpress-
ing cells. In contrast to our results, no inhibitory effect of 4-ME on
proliferation of endometrial, breast and cervical cancer cells has been
reported (26,27). This discrepancy may arise from the different con-
centrations of 4-ME used for experiments. Kato et al. and Gong et al.
measured cell viability at concentrations of 2 and 20 lM, respectively,
whereas we used 50 lM based on the results with different dosages
and indeed, cytotoxicity was observed at 30 lM of 4-ME in RCC cells
(Supplementary Figure 1 is available at Carcinogenesis Online). With
respect to 2-ME, the sensitivity of RCC cells is also different from that
of endometrial cancer cells. While 5 lM 2-ME was capable of re-
ducing viability of endometrial cancer cells by 30–35% (26,27), 70–
75% reduction was observed in RCC cells (Chang,I. and Tanaka,Y,
unpublished results). These data suggest that the growth-inhibitory
effect of 4-ME might be cell-type specific or require higher concen-
trations in RCC cells compared with endometrial cancer cells.
In summary, our study have shown that COMT expression is
decreased in human RCC and that ectopic COMT expression in
response to 4-OHE2 showed in vitro tumor suppressive abilities by
affecting proliferation and apoptosis. A further study showed that the
antiproliferative effect of COMT is due to 4-ME production and the
resultant induction of GADD45a. Our study demonstrates the impor-
tance of COMT in the prevention of RCC development and provides
support for COMT as a promising biomarker candidate and gene
therapy targets for treating human RCC.
Supplementary material
Supplementary Figure 1 can be found at http://carcin.oxfordjournals.
org/.
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Fig. 5. Inhibition of 4-OHE2-mediated apoptosis by GADD45a siRNA knock down. (A and B) Top, GADD45a siRNA suppress GADD45a protein expression.
Caki-1/COMT and ACHN/COMT cells (A) or parental Caki-1 and ACHN cells (B) were transfected with non-specific (NS) control or GADD45a siRNA. After
48 h, cells were lysed and subjected to western blot analysis. GAPDH was used as loading control. Bottom, GADD45a siRNA protects against cell death caused by
4-OHE2 or 4-ME. RCC cells were transfected with either NS control or GADD45a siRNA, maintained for 24 h and then treated with 4-OHE2 (A) or 4-ME (B) as
indicated. Early and late apoptotic cells were analyzed by flow cytometry. Values are expressed as mean ± standard error of mean of three independent
experiments. Asterisks denote statistically significant differences between values compared: P , 0.05.
Fig. 4. Induction of GADD45a in COMT-expressing RCC cells by 4-OHE2. (A and B) Induction of GADD45a mRNA (A) and protein (B) in COMT-expressing
Caki-1 and ACHN cells after 4-OHE2 exposure. Total mRNA or whole-cell lysates were extracted from pCMV6 or COMT expressing RCC cells treated with either
vehicle or 4-OHE2 (50 lM) for 48 h and subjected to quantitative reverse transcription–PCR (A) or western blot analysis (B), respectively. (C) Increased level of
GADD45a by 4-ME in parental RCC cells. Whole-cell lysates were extracted from cells incubated with 4-ME (50 lM) for 48 h and subjected to western blot
analysis. GAPDH was used as either a reference signal (A) or loading control (B and C). Values are expressed as the mean ± standard error of mean of three
independent experiments. Asterisks denote statistically significant differences between the compared values: P , 0.01; P , 0.001; n.s, non-significant.
COMT inhibits human RCC
425
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on Septem
ber 24, 2014
http://carcin.oxfordjournals.org/
D
ow
nloaded from
 
References
1.American Cancer Society. (2011) Cancer Facts & Figures. The Society,
Atlanta, GA, p. 13.
2.Lipworth,L. et al. (2009) Epidemiologic characteristics and risk factors for
renal cell cancer. Clin. Epidemiol., 1, 33–43.
3.Aron,M. et al. (2008) Impact of gender in renal cell carcinoma: an analysis
of the SEER database. Eur. Urol., 54, 133–140.
4.Woldrich,J.M. et al. (2008) Sex differences in renal cell cancer presentation
and survival: an analysis of the National Cancer Database, 1993-2004.
J. Urol., 179, 1709–1713; discussion 1713.
5.Bjornerem,A. et al. (2007) Circulating sex steroids, sex hormone-binding
globulin, and longitudinal changes in forearm bone mineral density in post-
menopausal women and men: the Tromso study. Calcif. Tissue Int., 81, 65–72.
6.Thomas,T. et al. (2000) Relationship of serum leptin levels with body
composition and sex steroid and insulin levels in men and women. Metab-
olism, 49, 1278–1284.
7.Bellet,R.E. et al. (1974) Estrogen-induced hypernephroma. J. Urol., 112,
160–161.
8.Nissenkorn,I. et al. (1979) Oestrogen-induced renal carcinoma. Br. J. Urol.,
51, 6–9.
9.Lindblad,P. et al. (1995) International renal-cell cancer study. V. Reproduc-
tive factors, gynecologic operations and exogenous hormones. Int. J. Can-
cer, 61, 192–198.
10.Kirkman,H. et al. (1950) Malignant renal tumors in male hamsters (Crice-
tus auratus) treated with estrogen. Cancer Res., 10, 122–124.
11.Li,J.J. et al. (1980) Inhibition of estrogen tumorigenesis in the Syrian
golden hamster kidney by antiestrogens. J. Natl Cancer Inst., 64, 795–800.
12.Zhu,B.T. et al. (1998) Functional role of estrogen metabolism in target
cells: review and perspectives. Carcinogenesis, 19, 1–27.
13.Chen,Z.H. et al. (2005) 4-Hydroxyestradiol induces oxidative stress and
apoptosis in human mammary epithelial cells: possible protection by NF-
kappaB and ERK/MAPK. Toxicol. Appl. Pharmacol., 208, 46–56.
14.Guldberg,H.C. et al. (1975) Catechol-O-methyl transferase: pharmacolog-
ical aspects and physiological role. Pharmacol. Rev., 27, 135–206.
15.Cavalieri,E.L. et al. (1997) Molecular origin of cancer: catechol estrogen-
3,4-quinones as endogenous tumor initiators. Proc. Natl Acad. Sci. USA,
94, 10937–10942.
16.Yager,J.D. et al. (1996) Molecular mechanisms of estrogen carcinogenesis.
Annu. Rev. Pharmacol. Toxicol., 36, 203–232.
17.Sutherland,T.E. et al. (2007) 2-Methoxyestradiol—a unique blend of ac-
tivities generating a new class of anti-tumour/anti-inflammatory agents.
Drug Discov. Today, 12, 577–584.
18.Zhu,B.T. et al. (1994) Quercetin increases the severity of estradiol-induced
tumorigenesis in hamster kidney. Toxicol. Appl. Pharmacol., 125, 149–158.
19.Zhu,B.T. et al. (1996) Inhibition of catechol O-methyltransferase-catalyzed
O-methylation of 2- and 4-hydroxyestradiol by quercetin. Possible role in
estradiol-induced tumorigenesis. J. Biol. Chem., 271, 1357–1363.
20.Salama,S.A. et al. (2008) Catecholestrogens induce oxidative stress and
malignant transformation in human endometrial glandular cells: protective
effect of catechol-O-methyltransferase. Int. J. Cancer, 123, 1246–1254.
21.Salama,S.A. et al. (2009) Catechol-o-methyltransferase expression and
2-methoxyestradiol affect microtubule dynamics and modify steroid recep-
tor signaling in leiomyoma cells. PLoS One, 4, e7356.
22.Tanaka,Y. et al. (2007) Polymorphisms of catechol-O-methyltransferase in
men with renal cell cancer. Cancer Epidemiol. Biomarkers Prev., 16, 92–
97.
23.Fisher,C. et al. (1994) Problems with p53 immunohistochemical staining:
the effect of fixation and variation in the methods of evaluation. Br. J.
Cancer, 69, 26–31.
24.Weisz,J. et al. (1998) Induction of nuclear catechol-O-methyltransferase by
estrogens in hamster kidney: implications for estrogen-induced renal can-
cer. Carcinogenesis, 19, 1307–1312.
25.Tenhunen,J. et al. (1994) Genomic organization of the human catechol
O-methyltransferase gene and its expression from two distinct promoters.
Eur. J. Biochem., 223, 1049–1059.
26.Kato,S. et al. (2007) The oestrogen metabolite 2-methoxyoestradiol alone
or in combination with tumour necrosis factor-related apoptosis-inducing
ligand mediates apoptosis in cancerous but not healthy cells of the human
endometrium. Endocr. Relat. Cancer, 14, 351–368.
27.Gong,Q.F. et al. (2011) 2ME and 2OHE2 exhibit growth inhibitory ef-
fects and cell cycle arrest at G2/M in RL95-2 human endometrial cancer
cells through activation of p53 and Chk1. Mol. Cell. Biochem., 352, 221–
230.
28.Meister,B. et al. (1993) Catechol-O-methyltransferase mRNA in the kidney
and its appearance during ontogeny. Kidney Int., 44, 726–733.
29.Li,S.A. et al. (1989) Variations in catechol O-methyltransferase activity in
rodent tissues: possible role in estrogen carcinogenicity. Carcinogenesis,
10, 63–67.
30.Xie,T. et al. (1999) Characterization and implications of estrogenic down-
regulation of human catechol-O-methyltransferase gene transcription. Mol.
Pharmacol., 56, 31–38.
31. Jiang,H. et al. (2003) Human catechol-O-methyltransferase down-regulation
by estradiol. Neuropharmacology, 45, 1011–1018.
32.Lachman,H.M. et al. (1996) Human catechol-O-methyltransferase phar-
macogenetics: description of a functional polymorphism and its potential
application to neuropsychiatric disorders. Pharmacogenetics, 6, 243–
250.
33.Nackley,A.G. et al. (2006) Human catechol-O-methyltransferase haplo-
types modulate protein expression by altering mRNA secondary structure.
Science, 314, 1930–1933.
34.Baylin,S.B. et al. (2000) DNA hypermethylation in tumorigenesis: epige-
netics joins genetics. Trends Genet., 16, 168–174.
35.Sasaki,M. et al. (2003) Multiple promoters of catechol-O-methyltransferase
gene are selectively inactivated by CpG hypermethylation in endometrial
cancer. Cancer Res., 63, 3101–3106.
36.Zhu,B.T. et al. (1996) Metabolic deglucuronidation and demethylation of
estrogen conjugates as a source of parent estrogens and catecholestrogen
metabolites in Syrian hamster kidney, a target organ of estrogen-induced
tumorigenesis. Toxicol. Appl. Pharmacol., 136, 186–193.
37.Dawling,S. et al. (2003) Methoxyestrogens exert feedback inhibition on
cytochrome P450 1A1 and 1B1. Cancer Res., 63, 3127–3132.
38.Cheng,Y. et al. (2007) 4-Methoxyestradiol-induced oxidative injuries
in human lung epithelial cells. Toxicol. Appl. Pharmacol., 220, 271–
277.
Received August 26, 2011; revised November 23, 2011;
accepted December 3, 2011
I.Chang et al.
426
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on Septem
ber 24, 2014
http://carcin.oxfordjournals.org/
D
ow
nloaded from
 
